Semi-Quantification of Her2/Neu Protein Expression in Formalin Fixed, Paraffin-Embedded Normal and Neoplastic Tissue
NCT ID: NCT02654444
Last Updated: 2016-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3 participants
OBSERVATIONAL
2013-05-31
2015-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classifying her2 immunohistochemical (IHC) stained samples.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification and Semi -Quantification of ER/PR Proteins Expression
NCT02654431
Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections
NCT01066507
Identification and Semi-Quantification of Ki-67 Protein Expression Status
NCT02654457
Immunohistochemical (IHC) Scoring for Receptors Expression in Breast Tissues
NCT00978276
HER2-PET Imaging in HER2-low Breast Cancers
NCT06732336
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GenASIs HiPath IHC #1
Expression of HER2 antibody. Semi-Quantitative value
No interventions assigned to this group
GenASIs HiPath IHC #2
Expression of HER2 antibody. Semi-Quantitative value
No interventions assigned to this group
GenASIs HiPath IHC #3
Expression of HER2 antibody. Semi-Quantitative value
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Borders of tumor nuclei are distinguishable
* Nuclei should have good integrity
* Background should not contain particles that interfere with the analysis
Exclusion Criteria
21 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Applied Spectral Imaging Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASI-HER2-IHC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.